Ulrich SchÃ¼ller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6573577/publications.pdf

Version: 2024-02-01

102	10,089	101543	37204
papers	citations	36	96
		h-index	g-index

104	104	104	11796
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
4	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
5	Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem Cells. Cancer Cell, 2008, 14, 135-145.	16.8	606
6	Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma. Cancer Cell, 2008, 14, 123-134.	16.8	572
7	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
8	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
9	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
10	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
11	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
12	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
13	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	7.7	162
14	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
15	SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathologica, 2014, 128, 453-456.	7.7	155
16	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
17	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica, 2012, 124, 875-881.	7.7	115
18	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112

#	Article	IF	Citations
19	Insulin-Like Growth Factor II Is Involved in the Proliferation Control of Medulloblastoma and Its Cerebellar Precursor Cells. American Journal of Pathology, 2005, 166, 1153-1162.	3.8	106
20	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
21	Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Science Translational Medicine, 2019, 11, .	12.4	100
22	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
23	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
24	Forkhead Transcription Factor FoxM1 Regulates Mitotic Entry and Prevents Spindle Defects in Cerebellar Granule Neuron Precursors. Molecular and Cellular Biology, 2007, 27, 8259-8270.	2.3	84
25	Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to⁶⁸Ga-DOTATATE/-TOC uptake. Neuro-Oncology, 2016, 18, now060.	1.2	79
26	Subgroup-specific immune and stromal microenvironment in medulloblastoma. OncoImmunology, 2018, 7, e1462430.	4.6	77
27	Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathologica, 2012, 123, 601-614.	7.7	71
28	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology, 2018, 20, 279-288.	1.2	71
29	Sonic Hedgehog promotes proliferation of Notch-dependent monociliated choroid plexus tumourÂcells. Nature Cell Biology, 2016, 18, 418-430.	10.3	59
30	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
31	Severe Alterations of Cerebellar Cortical Development after Constitutive Activation of Wnt Signaling in Granule Neuron Precursors. Molecular and Cellular Biology, 2011, 31, 3326-3338.	2.3	55
32	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathologica, 2014, 128, 123-136.	7.7	54
33	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathologica, 2014, 127, 931-933.	7.7	53
34	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021, 141, 291-301.	7.7	47
35	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
36	Î²-catenin function is required for cerebellar morphogenesis. Brain Research, 2007, 1140, 161-169.	2.2	46

#	Article	IF	Citations
37	Molecular characterization of histopathological ependymoma variants. Acta Neuropathologica, 2020, 139, 305-318.	7.7	43
38	Cerebellar â€˜transcriptomeâ€™ reveals cell-type and stage-specific expression during postnatal development and tumorigenesis. Molecular and Cellular Neurosciences, 2006, 33, 247-259.	2.2	42
39	EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene, 2020, 39, 3041-3055.	5.9	42
40	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
41	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	1.2	38
42	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. Nature Medicine, 2017, 23, 1191-1202.	30.7	38
43	Constitutive activation of Î²-Catenin in neural progenitors results in disrupted proliferation and migration of neurons within the central nervous system. Developmental Biology, 2013, 374, 319-332.	2.0	37
44	Loss of Smarc Proteins Impairs Cerebellar Development. Journal of Neuroscience, 2014, 34, 13486-13491.	3.6	36
45	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Journal of Neuropathology and Experimental Neurology, 2016, 75, 408-414.	1.7	35
46	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. Developmental Cell, 2018, 44, 709-724.e6.	7.0	35
47	Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. Cancer Immunology Research, 2019, 7, 1401-1411.	3.4	35
48	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	2.8	34
49	Wnt/Î²-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma. Acta Neuropathologica, 2014, 127, 605-607.	7.7	33
50	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. Nature Communications, 2021, 12, 5531.	12.8	31
51	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. European Journal of Human Genetics, 2018, 26, 1083-1093.	2.8	30
52	Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation. Cancer Gene Therapy, 2020, 27, 294-300.	4.6	29
53	Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. Brain Pathology, 2022, 32, e13068.	4.1	29
54	Proper cerebellar development requires expression of Î²1â€integrin in Bergmann glia, but not in granule neurons. Glia, 2012, 60, 820-832.	4.9	26

#	Article	IF	Citations
55	IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies. American Journal of Surgical Pathology, 2021, 45, 1190-1204.	3.7	26
56	Medulloblastoma: experimental models and reality. Acta Neuropathologica, 2017, 134, 679-689.	7.7	25
57	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. Acta Neuropathologica, 2020, 139, 913-936.	7.7	24
58	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. Acta Neuropathologica Communications, 2020, 8, 28.	5.2	24
59	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
60	Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressingMYCNinhGFAP-positive cells. Oncotarget, 2016, 7, 74415-74426.	1.8	21
61	TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma. Acta Neuropathologica, 2019, 137, 657-673.	7.7	20
62	Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathologica, 2021, 141, 323-325.	7.7	20
63	Dexamethasone Destabilizes Nmyc to Inhibit the Growth of Hedgehog-Associated Medulloblastoma. Cancer Research, 2010, 70, 5220-5225.	0.9	19
64	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
65	Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on <scp>DNA</scp> methylation. Journal of Pathology, 2022, 256, 378-387.	4.5	19
66	Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. Cancers, 2019, 11, 284.	3.7	18
67	DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. OncoImmunology, 2021, 10, 1932365.	4.6	17
68	TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Acta Neuropathologica, 2021, 141, 959-970.	7.7	16
69	Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup. Brain Pathology, 2021, 31, e12967.	4.1	16
70	Overexpression of Lin28b in Neural Stem Cells is Insufficient for Brain Tumor Formation, but Induces Pathological Lobulation of the Developing Cerebellum. Cerebellum, 2017, 16, 122-131.	2.5	14
71	<scp>SMARCA4</scp>â€deficient rhabdoid tumours show intermediate molecular features between <scp>SMARCB1</scp>â€deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. Journal of Pathology, 2021, 255, 1-15.	4.5	14
72	Primary central nervous system sarcoma with DICER1 mutationâ€”treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer, 2022, 128, 697-707.	4.1	14

#	Article	IF	Citations
73	The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma. PLoS Genetics, 2021, 17, e1009868.	3.5	14
74	The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration. Acta Neuropathologica Communications, 2019, 7, 199.	5.2	13
75	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	7.7	12
76	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathologica, 2021, 142, 873-886.	7.7	12
77	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	1.2	11
78	Histological subtype of medulloblastoma frequently changes upon recurrence. Acta Neuropathologica, 2015, 129, 459-461.	7.7	10
79	Cauda equina paragangliomas express HOXB13. Neuropathology and Applied Neurobiology, 2021, 47, 889-890.	3.2	9
80	Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. Nature Communications, 2022, 13, 1544.	12.8	9
81	Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. Brain Pathology, 2021, 31, 33-44.	4.1	8
82	Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas. Acta Neuropathologica, 2020, 140, 95-97.	7.7	7
83	Canonical Wnt Signaling Drives Tumor-Like Lesions from Sox2-Positive Precursors of the Murine Olfactory Epithelium. PLoS ONE, 2016, 11, e0166690.	2.5	7
84	A new ampliconâ€based gene panel for next generation sequencing characterization of meningiomas. Brain Pathology, 2022, 32, e13046.	4.1	7
85	Disruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development. Cell Death and Differentiation, 2022, 29, 1596-1610.	11.2	7
86	DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. Neuro-Oncology, 2022, 24, 1886-1897.	1.2	7
87	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
88	Treatment response of CNS highâ€grade neuroepithelial tumors with MN1 alteration. Pediatric Blood and Cancer, 2020, 67, e28627.	1.5	5
89	Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome. Acta Neuropathologica, 2021, 142, 591-593.	7.7	5
90	Brahma-related gene 1 has time-specific roles during brain and eye development. Development (Cambridge), 2021, 148, .	2.5	5

#	Article	IF	Citations
91	Double adenomas of the pituitary reveal distinct lineage markers, copy number alterations, and epigenetic profiles. Pituitary, 2021, 24, 904-913.	2.9	4
92	Simultaneous Brg1 Knockout and MYCN Overexpression in Cerebellar Granule Neuron Precursors Is Insufficient to Drive Tumor Formation but Temporarily Enhances their Proliferation and Delays their Migration. Cerebellum, 2021, 20, 410-419.	2.5	4
93	OUP accepted manuscript. Cerebral Cortex, 2020, 30, 1382-1392.	2.9	4
94	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	3.7	3
95	OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2022, 28, 4278-4291.	7.0	3
96	Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. Child's Nervous System, 2018, 34, 581-584.	1.1	2
97	Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities. Neuro-Oncology Advances, 2022, 4, vdab180.	0.7	2
98	An 8â€Yearâ€Old Girl with Posterior Fossa Mass. Brain Pathology, 2020, 30, 713-714.	4.1	1
99	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
100	Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma. Oncogenesis, 2021, 10, 78.	4.9	0
101	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. Pediatric Blood and Cancer, 2022, 69, e29594.	1.5	0
102	TBIO-07. Pediatric tumor classification through genome-wide methylation profiling of extracellular vesicle DNA. Neuro-Oncology, 2022, 24, i184-i184.	1.2	0